BEIJING: A breakthrough in flu treatment has arrived as Chinese regulators officially approved a new homegrown medication called onradivir — a first-in-class antiviral that works in a completely different way from traditional flu drugs. The China flu drug onradivir targets a specific protein in the influenza virus, and experts believe it could be a game-changer.
The treatment, developed by Raynovent in Guangzhou along with top respiratory research institutions, is designed to fight off uncomplicated cases of influenza A in adults. What makes onradivir stand out is that it goes after a protein called PB2, part of the flu virus’s RNA polymerase. This approach helps it work faster, hit harder, and avoid the resistance issues that often come with other treatments.
Health officials have described the approval as a big win for patients, especially as flu season keeps getting tougher worldwide. The medicine comes as a 0.6-gram tablet that patients take three times a day over five days — simple and easy for most to follow.
Raynovent says this is not just a scientific first, but a real solution from China to the global problem of flu. They’ve highlighted the drug’s speed and low resistance as major benefits. And with over a billion cases of flu each year around the world — and hundreds of thousands of deaths — any new option is welcome news.
By giving the green light to china flu drug onradivir, China is stepping up its role in global health innovation. With concerns about drug resistance on the rise, this approval might signal the start of a new era in how we treat flu.
